Supplementary Table. Comparison of baseline characteristics between AVD users and non-users within the tertiles of propensity scores

| | Lowest PS tertile | | | Middle PS tertile | | | Highest PS tertile | | |
|---|---|---|---|---|---|---|---|---|---|
| | AVD users (n = 7) | Non-users (n = 66) | *P* value | AVD users (n = 30) | Non-users (n = 43) | *P* value | AVD users (n = 55) | Non-users (n = 17) | *P* value |
| *Basic information* | | | | | | | | | |
| Age (year) | 58.5 ± 6.1 | 55.1 ± 11.1 | 0.808 | 46.3 ± 10.8 | 49.9 ± 12.4 | 0.102 | 45.0 ± 11.1 | 42.2 ± 11.1 | 0.822 |
| Male (%) | 85.7% | 71.2% | 0.413 | 46.7% | 51.2% | 0.705 | 67.3% | 70.6% | 0.798 |
| Body mass index | 23.8 (20.7 - 26.7) | 22.7 (20.6 - 24.9) | 0.459 | 21.3 (19.2 - 22.9) | 20.7 (19.0 - 24.1) | 0.937 | 20.7 (19.4 - 24.5) | 20.9 (19.3 - 22.4) | 0.701 |
| Time since transplant (year) | 4.4 (2.4 - 13.0) | 6.2 (2.3 - 14.1) | 0.549 | 13.5 (7.6 - 17.0) | 15.0 (5.2 - 19.3) | 0.929 | 13.6 (8.7 - 17.4) | 13.1 (8.2 - 17.2) | 0.995 |
| Dialysis vintage (year) | 2.7 (1.4 - 4.9) | 2.0 (0.6 - 5.4) | 0.399 | 1.8 (1.0 - 3.4) | 2.6 (1.1 - 5.2) | 0.361 | 2.4 (1.1 - 5.9) | 2.2 (1.1. - 2.6) | 0.210 |
| ABO incompatibility (%) | 50.0% | 29.1% | 0.294 | 3.9% | 10.5% | 0.328 | 8.3% | 13.3% | 0.565 |
| Living donor (%) | 85.7% | 86.4% | 0.962 | 86.7% | 83.7% | 0.729 | 94.1% | 80.0% | 0.172 |
| Donor age (year) | 51 (43 - 61) | 55 (40 - 60) | 0.933 | 51 (43 - 61) | 49 (39 - 60) | 0.770 | 52 (43 - 58) | 52 (49 - 57) | 0.863 |
| *Past history* | | | | | | | | | |
| Diabetes | | | 0.414 | | | 0.314 | | | 0.580 |
| Type 2 (%) | 0.0% | 4.6% | | 3.3% | 0.0% | | 1.8% | 5.9% | |
| NODAT (%) | 14.3% | 34.9% | | 10.0% | 4.7% | | 1.8% | 0.0% | |
| Hepatitis C virus (%) | 14.3% | 3.0% | 0.154 | 0.0% | 4.7% | 0.231 | 3.6% | 5.9% | 0.685 |
| Previous cancer (%) | 0.0% | 6.1% | 0.503 | 10.0% | 7.0% | 0.644 | 10.9% | 11.8% | 0.922 |
| *Medication* | | | | | | | | | |
| Calcineurin inhibitor | | | 0.635 | | | 0.620 | | | 0.816 |
| Cyclosporine (%) | 57.1% | 42.4% | | 56.7% | 67.4% | | 60.0% | 52.9% | |
| Tacrolimus (%) | 42.9% | 50.0% | | 30.0% | 20.9% | | 27.3% | 35.3% | |
| None (%) | 0.0% | 7.6% | | 13.3% | 11.6% | | 12.7% | 11.8% | |
| Antiproliferative agent | | | 0.302 | | | 0.638 | | | 0.583 |
| Azathioprine (%) | 14.3% | 3.0% | | 20.9% | 26.7% | | 34.6% | 41.2% | |
| Mycophenolate mofetil (%) | 85.7% | 74.2% | | 46.5% | 36.7% | | 43.6% | 41.2% | |
| Mizoribine (%) | 0.0% | 13.6% | | 20.9% | 30.0% | | 12.7% | 17.7% | |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| None (%) | 0.0% | 9.1% | | 11.6% | 6.7% | | 9.1% | 0.0% | |
| Predonisolone (%) | 100.0% | 98.5% | 0.743 | 96.7% | 95.4% | 0.780 | 98.2% | 100.0% | 0.576 |
| AVD | | | N/A | | | N/A | | | N/A |
| Calcitriol (%) | 71.4% | N/A | | 50.0% | N/A | | 32.7% | N/A | |
| (μg/day) | 0.63 (0.25 - 1.0) | N/A | | 0.5 (0.25 - 0.5) | N/A | | 0.5 (0.5 - 0.5) | N/A | |
| Alfacalcidol (%) | 28.6% | N/A | | 50.0% | N/A | | 67.3% | N/A | |
| (μg/day) | 0.25 (0.25 - 0.5) | N/A | | 0.5 (0.25 - 1.0) | N/A | | 0.5 (0.25 - 1.0) | N/A | |
| *Laboratory data* | | | | | | | | | |
| Albumin (mg/dL) | 4.3 ±0.3 | 4.3 ± 0.3 | 0.567 | 4.3 ±0.3 | 4.3 ± 0.3 | 0.642 | 4.2 ±0.3 | 4.3 ± 0.3 | 0.153 |
| Creatinine (mg/dL) | 1.34 (1.07 - 1.50) | 1.33 (1.02 - 1.76) | 0.993 | 1.32 (1.08 - 0.98) | 1.28 (0.95 - 1.56) | 0.277 | 1.62 (1.29 - 2.06) | 1.73 (1.43 - 2.01) | 0.863 |
| eGFR (ml/min per 1.73 $m^2$) | 44.1 ± 5.7 | 43.7 ± 2.0 | 0.527 | 40.7 ± 3.0 | 45.1 ± 2.4 | 0.130 | 36.7 ± 1.9 | 37.0 ± 2.9 | 0.464 |
| Corrected calcium (mg/dL) | 9.0 ± 0.4 | 9.2 ± 0.6 | 0.232 | 9.2 ±0.4 | 9.2 ± 0.6 | 0.490 | 9.3 ±0.5 | 9.2 ± 0.5 | 0.852 |
| Phosphate (mg/dL) | 2.9 (2.5 - 3.6) | 2.9 (2.7 - 3.3) | 0.970 | 3.1 (2.6 - 3.7) | 3.1 (2.8 - 3.5) | 0.995 | 3.2 (2.9 - 3.5) | 3.2 (2.9 - 3.4) | 0.915 |
| Intact PTH (pg/mL) | 88.9 (70.7 - 138.0) | 83.7 (64.4 - 123.0) | 0.506 | 73.6 (53.3 - 109.1) | 69.4 (48.6 - 88.3) | 0.297 | 41.3 (28.1 - 57.7) | 55.6 (41.5 - 63.1) | 0.029 |
| 25(OH)D (ng/mL) | 19.9 (10.6 - 37.0) | 15.0 (12.4 - 20.2) | 0.220 | 16.3 (12.3 - 19.5) | 17.9 (10.4 - 20.5) | 0.810 | 18.5 (13.8 - 23.9) | 20.7 (13.8 - 25.8) | 0.422 |
| Urinary protein ≥ 30 mg/dL (%) | 71.4% | 42.4% | 0.788 | 43.3% | 46.5% | 0.703 | 58.2% | 52.9% | 0.703 |
| Season of measurement | | | 0.103 | | | 0.493 | | | 0.756 |
| High UV-B season (%) | 72.7 | 42.9 | | 58.1 | 63.3 | | 41.2 | 36.4 | |
| Middle UV-B season (%) | 21.2 | 57.1 | | 37.2 | 26.7 | | 41.2 | 20.9 | |
| Low UV-B season (%) | 6.1 | 0.0 | | 4.7 | 10.0 | | 17.7 | 12.7 | |

Abbreviations: PS, propensity score; AVD, active vitamin D compounds; NODAT, new-onset diabetes after transplantation; eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D